Foundry Partners LLC Takes Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Foundry Partners LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,272 shares of the specialty pharmaceutical company’s stock, valued at approximately $492,000.

Other hedge funds have also made changes to their positions in the company. Assenagon Asset Management S.A. raised its position in Collegium Pharmaceutical by 411.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after purchasing an additional 291,286 shares during the last quarter. LSV Asset Management increased its stake in shares of Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 8.2% in the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after buying an additional 128,003 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Collegium Pharmaceutical by 119.6% during the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock worth $4,511,000 after buying an additional 79,823 shares in the last quarter. Finally, National Bank of Canada FI bought a new stake in Collegium Pharmaceutical during the 4th quarter worth about $1,855,000.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on COLL shares. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Truist Financial upped their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright lifted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 31st. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target (down previously from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Down 1.1 %

NASDAQ:COLL opened at $37.19 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The stock’s fifty day simple moving average is $35.01 and its 200-day simple moving average is $35.35. The firm has a market capitalization of $1.22 billion, a P/E ratio of 15.50 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.13 earnings per share. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.89 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.